{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:54:39Z","timestamp":1791982479212,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021708","name":"New South Wales Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.eclinm.2025.103101","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T02:55:32Z","timestamp":1742957732000},"page":"103101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["A methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney function"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4052-1970","authenticated-orcid":false,"given":"Geeta","family":"Sandhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangeline Armstrong","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2575-7910","authenticated-orcid":false,"given":"Josephine","family":"Adattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinkie","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5491-3460","authenticated-orcid":false,"given":"David W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisling","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Liauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8752-2551","authenticated-orcid":false,"given":"Andrew J.","family":"Mallett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Mirkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Scuderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Shingleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9562-083X","authenticated-orcid":false,"given":"Jim","family":"Siderov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Sprangers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9562-6326","authenticated-orcid":false,"given":"Brian N.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Tunnicliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn L.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.eclinm.2025.103101_bib1","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.urology.2011.04.035","article-title":"Utility of the R.E.N.A.L. nephrometry scoring system in objectifying treatment decision-making of the enhancing renal mass","volume":"78","author":"Canter","year":"2011","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103101_bib2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ejim.2011.05.005","article-title":"Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study","volume":"22","author":"Christiansen","year":"2011","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103101_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/j.ajkd.2013.07.008","article-title":"Reduced estimated GFR and cancer mortality","volume":"63","author":"Iff","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103101_bib4","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/sj.bjc.6605979","article-title":"Cancer and renal insufficiency results of the BIRMA study","volume":"103","author":"Janus","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eclinm.2025.103101_bib5","series-title":"KDIGO Clinical Practice Guideline for acute kidney injury","year":"2012"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103101_bib6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jnci\/djy167","article-title":"Acute kidney injury in patients receiving systemic treatment for cancer: a population-based cohort study","volume":"111","author":"Kitchlu","year":"2019","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103101_bib7","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1053\/j.ajkd.2022.02.020","article-title":"Cancer risk and mortality in patients with kidney disease: a population-based cohort study","volume":"80","author":"Kitchlu","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103101_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.thromres.2014.04.002","article-title":"Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality","volume":"134","author":"K\u00f6nigsbr\u00fcgge","year":"2014","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103101_bib9","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.semnephrol.2010.09.003","article-title":"Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA Study Group","volume":"30","author":"Launay-Vacher","year":"2010","journal-title":"Semin Nephrol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103101_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000091","article-title":"Renal insufficiency and cancer treatments","volume":"1","author":"Launay-Vacher","year":"2016","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103101_bib11","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22904","article-title":"Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study","volume":"110","author":"Launay-Vacher","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103101_bib12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000323740","article-title":"Chronic kidney disease in cancer patients: an independent predictor of cancer-specific mortality","volume":"33","author":"Na","year":"2011","journal-title":"Am J Nephrol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103101_bib13","first-page":"38","article-title":"Prevalence of anemia and chronic kidney disease in cancer patients: clinical significance for 1-year mortality","volume":"53","author":"Nakamura","year":"2011","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"10.1016\/j.eclinm.2025.103101_bib14","first-page":"91","article-title":"Getting the dose right: controversies in renal and hepatic dysfunction","volume":"14","author":"Kelly","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.eclinm.2025.103101_bib15","series-title":"Prescribing in renal impairment","year":"2022"},{"key":"10.1016\/j.eclinm.2025.103101_bib16","series-title":"Cancer drug manual","year":"2022"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103101_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/scipharm85010008","article-title":"Anticancer dose adjustment for patients with renal and hepatic dysfunction: from scientific evidence to clinical application","volume":"85","author":"Hendrayana","year":"2017","journal-title":"Sci Pharm"},{"key":"10.1016\/j.eclinm.2025.103101_bib18","series-title":"Dose adjustment for cytotoxics in renal impairment","year":"2009"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103101_bib19","first-page":"31","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103101_bib20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1053\/j.ackd.2017.10.003","article-title":"Pragmatic use of kidney function estimates for drug dosing: the tide is turning","volume":"25","author":"Hudson","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"issue":"23","key":"10.1016\/j.eclinm.2025.103101_bib21","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.cca.2011.07.012","article-title":"A\u00a0multicentric evaluation of IDMS-traceable creatinine enzymatic assays","volume":"412","author":"Pi\u00e9roni","year":"2011","journal-title":"Clin Chim Acta"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103101_bib22","article-title":"KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.eclinm.2025.103101_bib23","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"Clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.eclinm.2025.103101_bib24","series-title":"Handbook on grading the quality of evidence and the strength of recommendations using the GRADE approach: GRADE Working Group","author":"Sch\u00fcnemann","year":"2013"},{"key":"10.1016\/j.eclinm.2025.103101_bib25","series-title":"Cochrane Handbook for systematic reviews of interventions version 6.3","year":"2022"},{"key":"10.1016\/j.eclinm.2025.103101_bib26","series-title":"The guidelines manual","year":"2012"},{"key":"10.1016\/j.eclinm.2025.103101_bib27","series-title":"Guidelines for guidelines handbook","year":"2018"},{"key":"10.1016\/j.eclinm.2025.103101_bib28","series-title":"WHO handbook for guideline development","year":"2012"},{"issue":"Suppl 1","key":"10.1016\/j.eclinm.2025.103101_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2018-000848","article-title":"Considerations of complexity in rating certainty of evidence in systematic reviews: a primer on using the GRADE approach in global health","volume":"4","author":"Montgomery","year":"2019","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.eclinm.2025.103101_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2458-13-9","article-title":"Current experience with applying the GRADE approach to public health interventions: an empirical study","volume":"13","author":"Rehfuess","year":"2013","journal-title":"BMC Publ Health"},{"key":"10.1016\/j.eclinm.2025.103101_bib31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jclinepi.2021.01.001","article-title":"Challenges in applying the GRADE approach in public health guidelines and systematic reviews: a concept article from the GRADE Public Health Group","volume":"135","author":"Hilton","year":"2021","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103101_bib32","doi-asserted-by":"crossref","DOI":"10.1097\/JS9.0000000000000114","article-title":"Should the reporting certainty of evidence for meta-analysis of observational studies using GRADE be revisited?","volume":"109","author":"Yousefifard","year":"2023","journal-title":"Int J Surg"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103101_bib33","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/ajcn\/nqab124","article-title":"Grading nutrition evidence: where to go from here?","volume":"113","author":"Tobias","year":"2021","journal-title":"Am J Clin Nutr"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103101_bib34","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1634\/theoncologist.12-9-1070","article-title":"Commentary: oncologic drugs in patients with organ dysfunction: a summary","volume":"12","author":"Superfin","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.eclinm.2025.103101_bib35","series-title":"The Delphi method: techniques and applications","author":"Linstone","year":"1975"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103101_bib36","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","article-title":"Research guidelines for the Delphi survey technique","volume":"32","author":"Hasson","year":"2000","journal-title":"J\u00a0Adv Nurs"},{"key":"10.1016\/j.eclinm.2025.103101_bib37","series-title":"The RAND\/UCLA appropriateness method user\u2019s manual","author":"Fitch","year":"2001"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103101_bib38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2105\/AJPH.62.3.337","article-title":"The nominal group as a research instrument for exploratory health studies","volume":"62","author":"Van de Ven","year":"1972","journal-title":"Am J Public Health"},{"issue":"7001","key":"10.1016\/j.eclinm.2025.103101_bib39","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/bmj.311.7001.376","article-title":"Consensus methods for medical and health services research","volume":"311","author":"Jones","year":"1995","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103101_bib40","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1365-2753.2011.01807.x","article-title":"Bridging evidence and consensus methodology for inherited metabolic disorders: creating nutrition guidelines","volume":"19","author":"Singh","year":"2013","journal-title":"J\u00a0Eval Clin Pract"},{"key":"10.1016\/j.eclinm.2025.103101_bib41","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejca.2019.11.013","article-title":"The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients","volume":"127","author":"Alman","year":"2020","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103101_bib42","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/adc.85.2.132","article-title":"An evidence and consensus based guideline for acute diarrhoea management","volume":"85","author":"Armon","year":"2001","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.eclinm.2025.103101_bib43","series-title":"eviQ cancer treatments online","year":"2023"},{"key":"10.1016\/j.eclinm.2025.103101_bib44","series-title":"International consensus guideline on anticancer drug dosing in kidney dysfunction","author":"Sandhu","year":"2022"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103101_bib45","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"16","key":"10.1016\/j.eclinm.2025.103101_bib46","first-page":"6947","article-title":"Utilization of the PICO framework to improve searching PubMed for clinical question","volume":"7","author":"Schardt","year":"2007","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.eclinm.2025.103101_bib47","series-title":"GRADEpro guideline development tool [software]","author":"GRADEpro","year":"2021"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103101_bib48","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jclinepi.2011.06.004","article-title":"GRADE guidelines: 9. Rating up the quality of evidence","volume":"64","author":"Guyatt","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.eclinm.2025.103101_bib49","series-title":"NPSA rapid response report: reducing harm from omitted and delayed medicines in hospital. A tool to support local implementation","author":"Barrett","year":"2020"},{"key":"10.1016\/j.eclinm.2025.103101_bib50","series-title":"SurveyMonkey [software]","year":"2022"}],"updated-by":[{"DOI":"10.1016\/j.eclinm.2026.104275","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000}}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025000331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025000331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:44:31Z","timestamp":1786135471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025000331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":50,"alternative-id":["S2589537025000331"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103101","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney function","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103102","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103161","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103101"}}